Gilead to sell Viread at cost to 68 developing nations
BY Advocate.com Editors
April 08 2003 11:00 PM ET
Gilead Sciences announced Friday that the company will sell its HIV nucleotide reverse transcriptase inhibitor Viread at cost, approximately one tenth of its retail price, in 68 developing nations, the Los Angeles Times reports. The drug will be available for about $475 per person per year in every African nation as well as 15 other poor countries. Treatment programs in those countries can apply to purchase Viread at cost only, by mail or by fax. The company will choose eligible applications based on their ability to sustain an effective treatment program, adequately prescribe and monitor patients, and store the drug appropriately. The company also plans to manufacture the drug in a different color than it is sold in developing nations to prevent the cheaper medication from being reimported and sold in developed countries.
- 5 James Baldwin Quotes That Foreshadowed Ferguson
- #TBT: They Died in the Closet
- Another Lap for Michael Phelps’s Self-Proclaimed Girlfriend
- Why the Mississippi Marriage Win Is Our Most Important Yet
- Meet This Year's 'Prime Time 25'
- Texas AG: Same-Sex Couples' Request to Marry 'Untimely, Out of Order'